Growth is the process to increase cell mass and size by accumulation of newly synthesized proteins. It is increasingly appreciated as an important process in tumorigenesis, which is required to support the rapid cancer cell proliferation (an increase in cell number). The rate of protein synthesis is determined by both translational initiation and the abundance of ribosomes. Producing ribosomes or ribosome biogenesis involves several hundred genes and all three RNA polyrinerasesand accounts for 90% nuclear transcription. Ribosome biogenesis is highly energy-consuming and is tightly controlled by growth factors and nutrients. It has been long known that, in cancer cells, components of the translational machinery are deregulated or misexpressed. Several tumor suppressors and proto-oncogenes, such as the retinoblastoma (Rb) protein, p53, PTEN and Myc, have been shown to target ribosome biogenesis. Rapamycin is a promising new anticancer drug currently under large clinical trials. It is well tolerated and has shown excellent efficacy for many human cancers. We have recently obtained evidence that inhibition of ribosome biogenesis is crucial for rapamycin to inhibit cell growth, and discovered several new mechanisms for rapamycin to inhibit ribosome biogenesis. In this proposal, we will investigate the regulatory mechanisms of ribosome biogenesis, nucleolar size control and rapamycin inhibition. Accomplishment of these goals should advance the understanding of growth control, tumorigenesis and the mechanism of action by rapamycin. Additionally, such studies may lead to more effective anticancer therapeutic strategies and help identify new cancer drug targets in this important yet poorly studied area in cancer therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA123391-05
Application #
8018674
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
2007-04-01
Project End
2012-01-31
Budget Start
2011-02-01
Budget End
2012-01-31
Support Year
5
Fiscal Year
2011
Total Cost
$286,587
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Pharmacology
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Li, Yue; Tsang, Chi Kwan; Wang, Suihai et al. (2016) MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription. Hepatology 63:1928-42
Yang, X-Z; Li, X-X; Zhang, Y-J et al. (2016) Rab1 in cell signaling, cancer and other diseases. Oncogene 35:5699-5704
Che, Meixia; Wang, Ren; Li, Xiaoxing et al. (2016) Expanding roles of superoxide dismutases in cell regulation and cancer. Drug Discov Today 21:143-9
Meng, Ling-hua; Zheng, X F Steven (2015) Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin 36:1163-9
Wu, Tzung-Ju; Wang, Xiaowen; Zhang, Yanjie et al. (2015) Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase. Cell Rep 11:446-59
Zhang, Yanjie; Wang, Xiaowen; Qin, Xiaoyu et al. (2015) PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine 2:1944-56
Thomas, Janice D; Zhang, Yan-Jie; Wei, Yue-Hua et al. (2014) Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer Cell 26:754-69
Tsang, Chi Kwan; Liu, Yuan; Thomas, Janice et al. (2014) Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun 5:3446
Don, Aruni S Arachchige; Tsang, Chi Kwan; Kazdoba, Tatiana M et al. (2012) Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. Drug Discov Today 17:861-8
Zhang, Yanjie; Zheng, X F Steven (2012) mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 11:594-603

Showing the most recent 10 out of 16 publications